Information Provided By:
Fly News Breaks for March 28, 2018
DXCM
Mar 28, 2018 | 07:34 EDT
Canaccord analyst Kyle Rose noted Dexcom received FDA approval for its G6 system three months earlier than its best case scenario. He believes the approval brings meaningful enhancements to help close any competitive gaps from new entrants as its classification is as a Class ll device. Rose reiterated his Buy rating and $71 price target on Dexcom shares.
News For DXCM From the Last 2 Days
There are no results for your query DXCM